[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533606":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":31,"armGroups":26,"interventions":32,"overallOfficials":37,"centralContacts":42,"locations":52,"responsibleParty":92,"collaborators":95,"id":99,"slug":26,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":26,"enrollmentInfo":107,"targetDuration":110,"studyType":111,"phases":26,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Liege","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":26},[9,13,16,19],{"measure":10,"description":11,"timeFrame":12},"Difference in 95th centile of stride velocity between baseline and one year follow up- or last time point","95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).","1 year",{"measure":14,"description":15,"timeFrame":12},"Difference in 50th centile of stride velocity between baseline and one year follow up- or last time point","50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).",{"measure":17,"description":18,"timeFrame":12},"Difference in 95th centile of stride length between baseline and one year follow up- or last time point","95th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).",{"measure":20,"description":21,"timeFrame":12},"Difference in 50th centile of stride length between baseline and one year follow up- or last time point","50th centile of stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).",[23],{"measure":24,"description":25,"timeFrame":12},"Upper limb function evolution in patient with ALS","Upper limb function assessed with a magneto-inertial sensor (Actimyo°) in real-life.",null,{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":28,"timePerspective":29,"maskingInfo":26},"CASE_ONLY","PROSPECTIVE","On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores.\n\nParticipants will perform few tests (6-minutes walk test (6MWT), dynamometric measure, electromyography, and will answer to some questionaires (dysphagia handicap scale, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale).\n\nActimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.","Patients diagnosed with amyotrophic lateral sclerosis",[33],{"type":34,"name":35,"description":36,"armGroupLabels":26,"otherNames":26},"DEVICE","Actimyo","Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.",[38],{"name":39,"affiliation":40,"role":41},"Stéphanie Delstanche, MD","Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle","PRINCIPAL_INVESTIGATOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Laurie Medard","CONTACT","+3243218222","laurie.medard@citadelle.be",{"name":49,"role":45,"phone":50,"phoneExt":26,"email":51},"Margaux Poleur, MD","+3243216127","margaux.poleur@citadelle.be",[53,66,81],{"facility":54,"status":55,"city":56,"state":26,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":26},"Katholieke Universiteit Leuven","RECRUITING","Leuven","1425","Belgium","BE",{"type":61,"coordinates":62},"Point",[63,64],4.70093,50.87959,{"lat":64,"lon":63},{"facility":40,"status":55,"city":67,"state":26,"zip":68,"country":58,"countryCode":59,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Liège","4000",{"type":61,"coordinates":70},[71,72],5.56749,50.63373,{"lat":72,"lon":71},[75,79],{"name":76,"role":45,"phone":77,"phoneExt":26,"email":78},"Laurie Médard","043218222","Laurie.Medard@citadelle.be",{"name":80,"role":41,"phone":26,"phoneExt":26,"email":26},"Stéphanie Delstanche",{"facility":82,"status":83,"city":84,"state":26,"zip":26,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":91,"contacts":26},"Galaa Military Medical Complex","ACTIVE_NOT_RECRUITING","Cairo","Egypt","EG",{"type":61,"coordinates":88},[89,90],31.24967,30.06263,{"lat":90,"lon":89},{"type":41,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Laurent Servais","Professor",[96],{"name":97,"class":98},"SYSNAV","INDUSTRY","100533606",false,"NCT06228001","Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.","ActiALS","Inclusion Criteria:\n\n* Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.\n* Over 18 years old.\n* Signed informed consent\n* If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.\n\nExclusion Criteria:\n\n* Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.\n* Any other previous or present pathology having an impact on motor function.\n* Recent surgery or trauma (less than 6 months) in the upper or lower limbs.\n* Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.\n* Patients participating in an interventional clinical trial.","ALL","18 Years",{"count":108,"type":109},30,"ESTIMATED","5 Years","OBSERVATIONAL","ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.\n\nThe investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.",[114],"Amyotrophic Lateral Sclerosis",[35,116,117],"Accelerometry","Daily living","2025-05-15",{"date":120,"type":121},"2025-05-19","ACTUAL",{"date":123,"type":121},"2023-05-01",{"date":125,"type":109},"2028-01",{"name":5,"class":6},3]